# Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

> **NCT00412542** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 78 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Glioma

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** CPT-11
- **PROCEDURE:** MRI Scan
- **PROCEDURE:** Quantitative Sensory Tests (QST)

## Key facts

- **NCT ID:** NCT00412542
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2012-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412542, "Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00412542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*